Hims & Hers Shares Surge on Potential Novo Nordisk Partnership

Hims & Hers stock surges nearly 40% after reports of a distribution deal with Novo Nordisk, ending a patent lawsuit and clearing a major legal overhang for the telehealth firm.

A dramatic shift in sentiment propelled the stock of telehealth provider Hims & Hers in after-hours trading on Friday. Reports of an impending distribution agreement sent shares soaring by nearly 40%, potentially removing a significant legal overhang that has weighed on the company for months.

A Legal Battle Nears Its End

According to a report from Bloomberg News, Hims & Hers and pharmaceutical giant Novo Nordisk have reached a cooperative agreement. The deal would see the telehealth platform officially distribute the Danish company's weight-loss medications. Insiders suggest the partnership could be formally announced as soon as Monday.

This development marks a notable de-escalation. Novo Nordisk had filed a patent infringement lawsuit in February 2026 after Hims & Hers launched a lower-cost compounded semaglutide product for $49. The legal pressure forced Hims & Hers to withdraw that offering. A confirmed partnership would eliminate this regulatory uncertainty, which has more than halved the equity's value since the start of the year.

Strategic Moves Amid Challenges

The return to collaboration—a previous agreement was terminated in 2025—comes during a period of strategic expansion for Hims & Hers. While some investors, including JPMorgan, slightly reduced their holdings according to a March 5 filing, the company's management is pushing forward with international growth.

In late February, Hims & Hers announced the acquisition of Eucalyptus in a deal worth up to $1.15 billion. This move is designed to facilitate market entry into Australia and Japan, while also strengthening its presence in the United Kingdom and Germany.

Market attention is now firmly fixed on the start of the week. Should the companies confirm the cooperation on Monday, the threat of further costly legal battles would be lifted, clearing the path for Hims & Hers to operate freely in the crucial weight-management sector.